Congenital hypothyroidism in different cities of the Isfahan province: A descriptive retrospective study.
Congenital hypothyroidism
permanent congenital hypothyroidism
transient congenital hypothyroidism
Journal
Journal of education and health promotion
ISSN: 2277-9531
Titre abrégé: J Educ Health Promot
Pays: India
ID NLM: 101593794
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
07
2018
accepted:
19
03
2019
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
30
8
2019
Statut:
epublish
Résumé
Considering the high prevalence rate of congenital hypothyroidism CH in Iran, an epidemiological study in each region would be helpful in understanding the etiology of the disorder and providing preventative strategies in this field. This study aims to determine the prevalence of CH in different cities of the Isfahan province. This descriptive and retrospective study was conducted among 918 primarily diagnosed CH neonates, who have been identified through the neonatal screening program from 2009 to 2015. At the age of ≥3 years, treatment was discontinued for 4 weeks, and T4 and thyroid-stimulating hormone were measured. Permanent (PCH) or transient (TCH) was determined from the results of the thyroid function tests. From 389,101 screened neonates, 918 were diagnosed with primary CH. The overall prevalence rate of CH was 2.36 in 1000 live birth (ranged 1.58-7.22 in 1000 live birth in different cities). The highest prevalence rate of CH was reported in Ardestan, Khansar, Golpaygan, and Nain cities with prevalence rate of 4.86-7.22 in 1000 live birth and lowest prevalence occurring in Fereydan, Shahreza, Isfahan, and Mobarakeh cities with prevalence rate of 1.58-1.89 in 1000 live birth. In 392 cases which reached to 3 years of age, the rate of TCH was 47.45%. In Chadegan, Natanz, Fereydunshahr, Shahinshahr, Najafabad, Dehaghan, Borkhar, and Mobarakeh, the prevalence of PCH was <50%. The current findings indicate that the incidence rate of both PCH and TCH are high in Isfahan province with significant variability in different cities which could be due to the role of different genetic, prenatal, and different environmental factors. These epidemiological data could be used as baseline date to design more etiological studies.
Sections du résumé
BACKGROUND
BACKGROUND
Considering the high prevalence rate of congenital hypothyroidism CH in Iran, an epidemiological study in each region would be helpful in understanding the etiology of the disorder and providing preventative strategies in this field. This study aims to determine the prevalence of CH in different cities of the Isfahan province.
MATERIALS AND METHODS
METHODS
This descriptive and retrospective study was conducted among 918 primarily diagnosed CH neonates, who have been identified through the neonatal screening program from 2009 to 2015. At the age of ≥3 years, treatment was discontinued for 4 weeks, and T4 and thyroid-stimulating hormone were measured. Permanent (PCH) or transient (TCH) was determined from the results of the thyroid function tests.
RESULTS
RESULTS
From 389,101 screened neonates, 918 were diagnosed with primary CH. The overall prevalence rate of CH was 2.36 in 1000 live birth (ranged 1.58-7.22 in 1000 live birth in different cities). The highest prevalence rate of CH was reported in Ardestan, Khansar, Golpaygan, and Nain cities with prevalence rate of 4.86-7.22 in 1000 live birth and lowest prevalence occurring in Fereydan, Shahreza, Isfahan, and Mobarakeh cities with prevalence rate of 1.58-1.89 in 1000 live birth. In 392 cases which reached to 3 years of age, the rate of TCH was 47.45%. In Chadegan, Natanz, Fereydunshahr, Shahinshahr, Najafabad, Dehaghan, Borkhar, and Mobarakeh, the prevalence of PCH was <50%.
CONCLUSION
CONCLUSIONS
The current findings indicate that the incidence rate of both PCH and TCH are high in Isfahan province with significant variability in different cities which could be due to the role of different genetic, prenatal, and different environmental factors. These epidemiological data could be used as baseline date to design more etiological studies.
Identifiants
pubmed: 31463322
doi: 10.4103/jehp.jehp_219_18
pii: JEHP-8-137
pmc: PMC6691614
doi:
Types de publication
Journal Article
Langues
eng
Pagination
137Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Pediatr. 2004 May;144(5):643-7
pubmed: 15127002
J Pediatr Endocrinol Metab. 2004 Sep;17(9):1201-9
pubmed: 15506679
Clin Endocrinol (Oxf). 2005 Apr;62(4):444-8
pubmed: 15807875
J Clin Endocrinol Metab. 2005 Dec;90(12):6361-3
pubmed: 16144951
J Matern Fetal Neonatal Med. 2007 Jun;20(6):473-6
pubmed: 17674257
East Mediterr Health J. 2007 May-Jun;13(3):567-74
pubmed: 17687829
Acta Paediatr Jpn. 1991 Jun;33(3):363-8
pubmed: 1785333
J Med Screen. 2009;16(1):11-6
pubmed: 19349525
J Pediatr Endocrinol Metab. 2010 Aug;23(8):815-26
pubmed: 21073124
J Trop Pediatr. 2012 Feb;58(1):79-80
pubmed: 21296863
J Clin Endocrinol Metab. 2011 May;96(5):E841-5
pubmed: 21367925
Int J Prev Med. 2010 Spring;1(2):92-7
pubmed: 21566768
Indian J Endocrinol Metab. 2011 Jul;15(Suppl 2):S117-20
pubmed: 21966647
J Pediatr Endocrinol Metab. 2012;25(1-2):13-29
pubmed: 22570946
J Clin Res Pediatr Endocrinol. 2012 Jun;4(2):72-5
pubmed: 22672863
J Pediatr. 2013 Jan;162(1):177-82
pubmed: 22878110
Med Glas (Zenica). 2012 Aug;9(2):341-4
pubmed: 22926374
Iran J Pediatr. 2011 Jun;21(2):188-92
pubmed: 23056786
J Clin Res Pediatr Endocrinol. 2013;5 Suppl 1:8-12
pubmed: 23154158
Adv Biomed Res. 2012;1:37
pubmed: 23326768
J Clin Res Pediatr Endocrinol. 2013;5(2):73-9
pubmed: 23748057
PLoS One. 2013 Jun 28;8(6):e68048
pubmed: 23840807
J Res Med Sci. 2013 Aug;18(8):699-703
pubmed: 24379847
Int J Prev Med. 2013 Dec;4(12):1365-70
pubmed: 24498491
Adv Biomed Res. 2014 Jan 09;3:21
pubmed: 24600601
Clin Pediatr Endocrinol. 2015 Apr;24(2):59-62
pubmed: 26019402
Curr Opin Endocrinol Diabetes Obes. 2015 Oct;22(5):407-12
pubmed: 26313902
Pediatr Neonatol. 2017 Oct;58(5):442-448
pubmed: 28412200
Transl Pediatr. 2017 Oct;6(4):349-358
pubmed: 29184815
J Trop Pediatr. 1996 Dec;42(6):348-51
pubmed: 9009561